Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity - PubMed (original) (raw)
. 2003 Jul;306(1):124-31.
doi: 10.1124/jpet.103.049858. Epub 2003 Mar 27.
Affiliations
- PMID: 12663688
- DOI: 10.1124/jpet.103.049858
Free article
Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity
Heidrun Potschka et al. J Pharmacol Exp Ther. 2003 Jul.
Free article
Abstract
The blood-brain barrier (BBB) is a physical and metabolic barrier between the brain and the systemic circulation, which functions to protect the brain from circulating drugs, toxins, and xenobiotics. ATP-dependent multidrug transporters such as P-glycoprotein (Pgp; ABCB1), which are found in the apical (luminal) membranes of brain capillary endothelial cells, are thought to play an important role in BBB function by limiting drug penetration into the brain. More recently, the multidrug resistance protein MRP2 (ABCC2) has been found in the luminal surface of brain capillary endothelium of different species, including humans. In endothelial cells from patients with drug-resistant epilepsy, MRP2 was shown to be overexpressed, indicating that it may be critically involved in multidrug resistance of such patients. However, the role of MRP2 in drug disposition into the brain is defined poorly. Herein, we used different strategies to study the contribution of MRP2 to BBB function. First, the MRP inhibitor probenecid was shown to increase extracellular brain levels of the major antiepileptic drug phenytoin in rats, indicating that phenytoin is a substrate of MRP2 in the BBB. This was substantiated by using MRP2-deficient TR- rats, in which extracellular brain levels of phenytoin were significantly higher compared with the normal background strain. In the kindling model of epilepsy, coadministration of probenecid significantly increased the anticonvulsant activity of phenytoin. In kindled MRP2-deficient rats, phenytoin exerted a markedly higher anticonvulsant activity than in normal rats. These data indicate that MRP2 substantially contributes to BBB function.
Similar articles
- Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
Potschka H, Fedrowitz M, Löscher W. Potschka H, et al. Epilepsia. 2003 Dec;44(12):1479-86. doi: 10.1111/j.0013-9580.2003.22603.x. Epilepsia. 2003. PMID: 14636316 - Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain.
Potschka H, Löscher W. Potschka H, et al. Neuroreport. 2001 Aug 8;12(11):2387-9. doi: 10.1097/00001756-200108080-00020. Neuroreport. 2001. PMID: 11496115 - Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition.
Gerk PM, Vore M. Gerk PM, et al. J Pharmacol Exp Ther. 2002 Aug;302(2):407-15. doi: 10.1124/jpet.102.035014. J Pharmacol Exp Ther. 2002. PMID: 12130697 Review. - Membrane transporter proteins: a challenge for CNS drug development.
Girardin F. Girardin F. Dialogues Clin Neurosci. 2006;8(3):311-21. doi: 10.31887/DCNS.2006.8.3/fgirardin. Dialogues Clin Neurosci. 2006. PMID: 17117613 Free PMC article. Review.
Cited by
- Acute and Chronic Administrations of Rheum palmatum Reduced the Bioavailability of Phenytoin in Rats: A New Herb-Drug Interaction.
Chi YC, Juang SH, Chui WK, Hou YC, Chao PD. Chi YC, et al. Evid Based Complement Alternat Med. 2012;2012:701205. doi: 10.1155/2012/701205. Epub 2012 Jul 8. Evid Based Complement Alternat Med. 2012. PMID: 22829856 Free PMC article. - Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.
Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Davenport JM, et al. J Clin Pharmacol. 2015 May;55(5):534-42. doi: 10.1002/jcph.442. Epub 2015 Jan 14. J Clin Pharmacol. 2015. PMID: 25491493 Free PMC article. Clinical Trial. - SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers.
Morris ME, Rodriguez-Cruz V, Felmlee MA. Morris ME, et al. AAPS J. 2017 Sep;19(5):1317-1331. doi: 10.1208/s12248-017-0110-8. Epub 2017 Jun 29. AAPS J. 2017. PMID: 28664465 Free PMC article. Review. - Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.
Markowicz-Piasecka M, Markiewicz A, Darłak P, Sikora J, Adla SK, Bagina S, Huttunen KM. Markowicz-Piasecka M, et al. Neurotherapeutics. 2022 Apr;19(3):942-976. doi: 10.1007/s13311-022-01228-5. Epub 2022 Apr 7. Neurotherapeutics. 2022. PMID: 35391662 Free PMC article. Review. - Influence of efflux transporters on drug metabolism: theoretical approach for bioavailability and clearance prediction.
Fagiolino P, Vázquez M, Eiraldi R, Maldonado C, Scaramelli A. Fagiolino P, et al. Clin Pharmacokinet. 2011 Feb;50(2):75-80. doi: 10.2165/11539230-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21241069 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous